Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

(2020) Sufang Tian et al.   Journal of Thoracic Oncology

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Is COVID-19 receiving ADE from other coronaviruses?

(2020) Jason A. Tetro   MICROBES AND INFECTION

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

(2020) Renhong Yan et al.   SCIENCE

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

(2020) Zhe Xu et al.   Lancet Respiratory Medicine

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

(2020) Chuan Qin et al.   CLINICAL INFECTIOUS DISEASES

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

(2020) Chenguang Shen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

(2020) Kai Duan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

(2020) Ling Li et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

(2020) Michael J. Joyner et al.   JOURNAL OF CLINICAL INVESTIGATION

The National Early Warning Score 2 (NEWS2)

(2019) Gary B Smith et al.   CLINICAL MEDICINE

Epidemiology and Immune Pathogenesis of Viral Sepsis

(2018) Gu-Lung Lin et al.   Frontiers in Immunology

Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs

(2017) Apolline Salama et al.   TRANSPLANTATION

Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization

(2016) Yujia Li et al.   VIROLOGY

A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty

(2014) Jordi Cortés et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects

(2013) Laurent Cotte et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS